Custom AAV Packaging and Production Services

AAV capsid proteins play a crucial role in gene therapy and vaccine development. However, traditional directed evolution screening techniques have limitations such as limited library capacity, low success rate, and low screening efficiency. To address this issue, Cyagen has developed a predictive AI model using deep learning to efficiently screen AAV mutants for multi-target gene therapy drugs. This model enables us to achieve targeted predictions for various sites, such as brain targeting, full ocular expression capability, and ocular penetration.

Compared to traditional directed evolution, AI-assisted screening of AAV has achieved multidimensional breakthroughs, including:

Limitless library capacity

Taking the traditional AAV9 561-588 amino acid region mutant library as an example, the maximum capacity of the DNA library is 10⁹, while the sequence capacity achieved through AI deep learning screening can reach 10⁵⁰.

Using AI models instead of wet lab experiments to generate new sequences

AI is used to screen parameters such as high yield and tissue targeting, and then the data is synthesized through the AI model algorithms to suggest capsid designs anticipated to have high productivity and tissue delivery. This effectively avoids the limitations of library synthesis capacity in traditional wet lab experiments.

Shortened screening cycle from at least 3 years to approximately 1 year, leading to a 3-6 times increase in efficiency

To obtain the optimal mutant in traditional directed evolution, it often requires 3-6 rounds of experiments from library synthesis to screening. By utilizing AI technology, enough data can be obtained through 1-2 rounds of screening.

Brain targeting prediction

Figure 1. Brain targeting prediction

Figure 2. Perform intravenous tail injection with 3E11 vg (viral genomes) per mouse and evaluate after 3 weeks.

Prediction of overall ocular expression capability

Figure 3. Prediction of AAV overall ocular expression efficiency

Figure 4. Intravitreal injection of 1E10 vg/eye and detection of overall ocular anti-VEGF protein levels after 27 days.

Prediction of ocular penetration ability

Figure 5. Prediction of AAV ocular penetration efficiency.

Figure 6. Intravitreal injection of 3E9 vg/eye and fluorescence imaging of the fundus at 18 days, followed by histological analysis of retinal sections at 21 days to assess viral expression efficiency.

Cyagen offers a range of services from AAV vector design and construction to virus packaging, purification, expression analysis, and functional validation. These services aim to minimize the experimental timeline for clients. Various titer specifications are available, and stringent purification processes are employed to ensure efficient expression of exogenous human/mouse ORFs, shRNA, lncRNA, and CRISPR/gRNA.

Promotion Period: July 14^th to September 14^th, 2023

Event Details: Enjoy a 40% discount on the following virus packaging services, with fast delivery within 3 weeks, plus a complimentary standard control virus.

Service	Type	Specifications	Titer	Discounted price	Order
AAV packaging	Normal serotype	1E+12GC	≥5E+12GC/ml	$1800	Order
	AAV1、8、9 and php.eb	5E+12GC	≥1E+13GC/ml	$3500	Order
		1E+13GC	≥1E+13GC/ml	$4500	Order

AAV infection of cells in vitro

We infected 293T cells with AAV2, AAV8, and AAV9 at MOI (multiplicity of infection) values of 1E5, 1E4, 1E3, and 1E2, respectively. After 48 hours, we observed significant fluorescence intensity. Among them, AAV2 (MOI=1E5) achieved a GFP positive rate of 99.66%.

Obtaining the virus through packaging is just the beginning, as there are still important steps such as injection into animal bodies and subsequent efficacy evaluations, which have a significant impact on the success of the project. Cyagen can provide a variety of AAV vector injection services for mice, including common routes such as tail vein, intraperitoneal, ocular, brain, and intramuscular injections. We can also help you access downstream drug efficacy service platforms, enabling you to obtain accurate research conclusions through physiological and biochemical analysis, pathology analysis, metabolism analysis, gene and protein expression analysis, and cell function testing to better utilize phenotype verification.

Intravitreal injection (into the subretinal/vitreous cavity of the eye)

Stereotactic injection into the hippocampus/lateral ventricle of the brain

Intratracheal (pulmonary) injection

Intrathecal injection (into the brain/spinal cord)